Abali, H. Et Al. 2018. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).. Gastrointestinal Cancers Symposium , (San-Francisco, Costa Rica).

Abali, H., Yalcin, S., Onal, C., Dane, F., Oksuzoglu, B., Ozdemir, N., ... Mertsoylu, H.(2018). A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study). . Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica

Abali, HÜSEYİN Et Al. "A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).," Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 2018

Abali, HÜSEYİN Et Al. "A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica, 2018

Abali, H. Et Al. (2018) . "A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica.

@conferencepaper{conferencepaper, author={HÜSEYİN ABALI Et Al. }, title={A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).}, congress name={Gastrointestinal Cancers Symposium}, city={San-Francisco}, country={Costa Rica}, year={2018}}